JP2012522508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522508A5 JP2012522508A5 JP2012503638A JP2012503638A JP2012522508A5 JP 2012522508 A5 JP2012522508 A5 JP 2012522508A5 JP 2012503638 A JP2012503638 A JP 2012503638A JP 2012503638 A JP2012503638 A JP 2012503638A JP 2012522508 A5 JP2012522508 A5 JP 2012522508A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- level
- increased
- fold
- gene product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 108091070501 miRNA Proteins 0.000 claims description 42
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 37
- 108091055140 miR-574 stem-loop Proteins 0.000 claims description 26
- 108091058485 miR-574-1 stem-loop Proteins 0.000 claims description 26
- 108091055064 miR-574-2 stem-loop Proteins 0.000 claims description 26
- 239000012472 biological sample Substances 0.000 claims description 23
- 108091027121 Epstein Barr virus miR-BART19 stem-loop Proteins 0.000 claims description 20
- 108091028751 miR-188 stem-loop Proteins 0.000 claims description 20
- 230000007423 decrease Effects 0.000 claims description 19
- 108091043720 miR-513 stem-loop Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 108091046841 MiR-150 Proteins 0.000 claims description 16
- 108091060425 Epstein Barr virus miR-BART13 stem-loop Proteins 0.000 claims description 14
- 108091059964 miR-154 stem-loop Proteins 0.000 claims description 14
- 108091045665 miR-202 stem-loop Proteins 0.000 claims description 14
- 108091028761 miR-409 stem-loop Proteins 0.000 claims description 14
- 108091053257 miR-99b stem-loop Proteins 0.000 claims description 14
- 108091057331 miR-509 stem-loop Proteins 0.000 claims description 13
- 108091047658 miR-564 stem-loop Proteins 0.000 claims description 13
- -1 miR-768-3p Proteins 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 108091063344 miR-30b stem-loop Proteins 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 210000003079 salivary gland Anatomy 0.000 claims description 8
- 210000003296 saliva Anatomy 0.000 claims description 7
- 108091028066 Mir-126 Proteins 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 108091026375 miR-135b stem-loop Proteins 0.000 claims description 6
- 108091086065 miR-135b-2 stem-loop Proteins 0.000 claims description 6
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims description 6
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims description 6
- 108091023968 miR-330 stem-loop Proteins 0.000 claims description 6
- 108091055145 miR-342 stem-loop Proteins 0.000 claims description 6
- 108091048782 miR-501 stem-loop Proteins 0.000 claims description 6
- 108091063911 miR-650 stem-loop Proteins 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108091062170 Mir-22 Proteins 0.000 claims description 2
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108091029500 miR-183 stem-loop Proteins 0.000 claims description 2
- 108091074450 miR-200c stem-loop Proteins 0.000 claims description 2
- 108091042879 miR-326 stem-loop Proteins 0.000 claims description 2
- 108091029997 miR-328 stem-loop Proteins 0.000 claims description 2
- 108091029118 miR-548c stem-loop Proteins 0.000 claims description 2
- 108091092453 miR-548c-1 stem-loop Proteins 0.000 claims description 2
- 108091030775 miR-548c-2 stem-loop Proteins 0.000 claims description 2
- 108091072773 miR-585 stem-loop Proteins 0.000 claims description 2
- 108091047084 miR-9 stem-loop Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 210000000258 minor salivary gland Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 108091078999 miR-56 stem-loop Proteins 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16514209P | 2009-03-31 | 2009-03-31 | |
| US61/165,142 | 2009-03-31 | ||
| PCT/US2010/029307 WO2010117829A2 (en) | 2009-03-31 | 2010-03-31 | Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012522508A JP2012522508A (ja) | 2012-09-27 |
| JP2012522508A5 true JP2012522508A5 (https=) | 2013-03-28 |
Family
ID=42936826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503638A Pending JP2012522508A (ja) | 2009-03-31 | 2010-03-31 | シェーグレン症候群の診断および治療のためのバイオマーカーとしての示差的に発現されるマイクロｒｎａ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8785414B2 (https=) |
| EP (1) | EP2414549A4 (https=) |
| JP (1) | JP2012522508A (https=) |
| AU (1) | AU2010234806B2 (https=) |
| CA (1) | CA2754412A1 (https=) |
| WO (1) | WO2010117829A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2626540C2 (ru) * | 2011-04-18 | 2017-07-28 | Диамир, Ллс | Способы обнаружения патологических изменений в органе или системе органов |
| US20140275211A1 (en) * | 2011-06-21 | 2014-09-18 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
| US10006919B2 (en) | 2013-03-15 | 2018-06-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Peptide array quality control |
| US9970932B2 (en) | 2013-03-15 | 2018-05-15 | Arizona Board Of Regents On Behalf Of Arizona State University | Non-covalent patterned chemical features and use thereof in MALDI-based quality control |
| CN105917005B (zh) | 2013-11-18 | 2020-09-11 | 迪阿米尔有限责任公司 | 使用来自体液的miRNA检测和监控帕金森病(PD)的方法 |
| KR102753113B1 (ko) * | 2015-09-18 | 2025-01-09 | 바나디스 다이아그노스틱스 | Dna 샘플의 분석을 위한 프로브 세트 및 이의 사용 방법 |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| US11149313B2 (en) | 2016-03-21 | 2021-10-19 | Diamir, Llc | Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases |
| US10781487B2 (en) | 2017-07-24 | 2020-09-22 | Diamir, Llc | miRNA-based methods for detecting and monitoring aging |
| US12415171B2 (en) | 2018-12-21 | 2025-09-16 | Microsoft Technology Licensing, Llc | Regulation of DNA synthesis by nucleotides linked to protecting groups |
| US11584956B2 (en) | 2018-12-21 | 2023-02-21 | Microsoft Technology Licensing, Llc | Selectively controllable cleavable linkers |
| GB201901120D0 (en) * | 2019-01-28 | 2019-03-20 | Imperial Innovations Ltd | Methods |
| US12226746B2 (en) * | 2019-06-07 | 2025-02-18 | Microsoft Technology Licensing, Llc | Reversing bias in polymer synthesis electrode array |
| US11773422B2 (en) | 2019-08-16 | 2023-10-03 | Microsoft Technology Licensing, Llc | Regulation of polymerase using cofactor oxidation states |
| US11795450B2 (en) | 2019-09-06 | 2023-10-24 | Microsoft Technology Licensing, Llc | Array-based enzymatic oligonucleotide synthesis |
| US11896945B2 (en) | 2019-10-09 | 2024-02-13 | Microsoft Technology Licensing, Llc | High surface area coatings for solid-phase synthesis |
| EP4370712A1 (en) * | 2021-07-16 | 2024-05-22 | Exosome Diagnostics, Inc. | Methods of detecting sjögren's syndrome using salivary exosomes |
| WO2023172087A1 (ko) * | 2022-03-11 | 2023-09-14 | 연세대학교 산학협력단 | Klk5, klk7, cstb, ube2v2, tmsb10 또는 pi3을 유효성분으로 포함하는 쇼그렌 증후군 진단용 바이오마커 조성물 |
| WO2024054572A1 (en) * | 2022-09-07 | 2024-03-14 | Exosome Diagnostics, Inc. | Methods of detecting sjögren's syndrome using salivary exosomes |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635563B2 (en) | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| EP2302055B1 (en) | 2004-11-12 | 2014-08-27 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| US20060185027A1 (en) * | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| EP1969147B1 (en) * | 2006-01-05 | 2014-07-30 | The Ohio State University Research Foundation | microRNA-based methods for the diagnosis of stomach cancer |
| ES2553442T3 (es) | 2006-01-05 | 2015-12-09 | The Ohio State University Research Foundation | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
| EP2007888A2 (en) | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| WO2008147430A2 (en) * | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| WO2008147974A1 (en) * | 2007-05-23 | 2008-12-04 | University Of South Florida | Micro-rnas modulating immunity and inflammation |
| KR20110005783A (ko) * | 2008-02-08 | 2011-01-19 | 메디뮨 엘엘씨 | 질환 마커 및 그의 용도 |
| WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
-
2010
- 2010-03-31 JP JP2012503638A patent/JP2012522508A/ja active Pending
- 2010-03-31 WO PCT/US2010/029307 patent/WO2010117829A2/en not_active Ceased
- 2010-03-31 EP EP10762205.2A patent/EP2414549A4/en not_active Withdrawn
- 2010-03-31 US US13/262,125 patent/US8785414B2/en not_active Expired - Fee Related
- 2010-03-31 AU AU2010234806A patent/AU2010234806B2/en not_active Ceased
- 2010-03-31 CA CA2754412A patent/CA2754412A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522508A5 (https=) | ||
| Moorlag et al. | β-Glucan induces protective trained immunity against Mycobacterium tuberculosis infection: a key role for IL-1 | |
| Cui et al. | Lung myofibroblasts promote macrophage profibrotic activity through lactate-induced histone lactylation | |
| Zhu et al. | MicroRNA-486-5p targeting PTEN protects against coronary microembolization-induced cardiomyocyte apoptosis in rats by activating the PI3K/AKT pathway | |
| Liu et al. | MicroRNA-135a and-200b, potential Biomarkers for Alzheimer׳ s disease, regulate β secretase and amyloid precursor protein | |
| Lai et al. | Non-invasive transcutaneous vagal nerve stimulation improves myocardial performance in doxorubicin-induced cardiotoxicity | |
| He et al. | Inhibition of microRNA-124 reduces cardiomyocyte apoptosis following myocardial infarction via targeting STAT3 | |
| Lai et al. | M2C polarization by baicalin enhances efferocytosis via upregulation of MERTK receptor | |
| Zissler et al. | Allergen‐specific immunotherapy induces the suppressive secretoglobin 1A1 in cells of the lower airways | |
| ES2724549T3 (es) | ARN pequeños derivados de RNY como biomarcadores para trastornos relacionados con la aterosclerosis | |
| Stone et al. | Genomics of human fibrotic diseases: disordered wound healing response | |
| Sanders et al. | Epigenetic regulation of caveolin-1 gene expression in lung fibroblasts | |
| CN111356774A (zh) | 用于检测衰老细胞的新型生物标记物 | |
| Morán et al. | Circulating levels of miR-150 are associated with poorer outcomes of A/H1N1 infection | |
| Pu et al. | Alterations and potential applications of gut microbiota in biological therapy for inflammatory bowel diseases | |
| Tang et al. | Acinar cell-derived extracellular vesicle MiRNA-183-5p aggravates acute pancreatitis by promoting M1 macrophage polarization through downregulation of FoxO1 | |
| Jin et al. | IL‑35 may maintain homeostasis of the immune microenvironment in periodontitis | |
| WO2019229259A1 (en) | Materials and methods for monitoring the development of resistance of cancers to treatment | |
| Singh et al. | Idiopathic pulmonary fibrosis: where do we stand and how far to go | |
| Xu et al. | Silencing XIST mitigated lipopolysaccharide (LPS)-induced inflammatory injury in human lung fibroblast WI-38 cells through modulating miR-30b-5p/CCL16 axis and TLR4/NF-κB signaling pathway | |
| Zhu et al. | Low‐intensity pulsed ultrasound alleviates doxorubicin‐induced cardiotoxicity via inhibition of S100a8/a9‐mediated cardiac recruitment of neutrophils | |
| Can et al. | Some miRNA expressions and their targets in ischemic stroke | |
| EP2622075B1 (en) | Use of mirnas for the diagnosis, prophylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities | |
| Ren et al. | Diagnostic significance of LncRNA MIAT in periodontitis and the molecular mechanisms influencing periodontal ligament fibroblasts via the miR-204-5p/DKK1 axis | |
| Chen et al. | A novel STAT3/NFκB p50 axis regulates stromal-KDM2A to promote M2 macrophage-mediated chemoresistance in breast cancer |